anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Subjects in the Influsplit Tetra_LP group aged between 3 years to \<9 years received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by licensed process (LP). Subjects aged 9-17 years received only 1 dose of Influsplit Tetra™ vaccine produced by LP at Day 0. Influsplit Tetra™ vaccine produced by LP was administered intramuscularly in the deltoid region of left or non-dominant arm (Day 0) and in the deltoid region of right or dominant arm (Day 28).
FIELD: biotechnology, medicine. SUBSTANCE: invention relates to the development of live vaccine against HIV using attenuated strain Salmonella constructed for expression of specific HIV proteins on its surface. Invention relates to two developed recombinant plasmids comprising genes Lpp- OmpA required for surface exposition, genes encoding proteins HIV-1 arranged followed by, namely, reverse transcriptase protein or trans-activating protein (Tat). Indicated plasmids are administrated in attenuated strain Salmonella SL3261 by electroporation and antigen expression is confirmed. Then indicated live vaccines are used for oral inoculation in mice. Feces from vaccinated mice are tested for IgA-response and responses of helper T-cells specific for these HIV antigens are recorded. EFFECT: expanded assortment of agents against HIV-infection, valuable medicinal and antiviral properties. 9 cl, 14 dwg, 1 tbl, 12 ex
Before the chemotherapy, patients in intervention group will use cooling cap 30 minutes before chemotherapy. Once chemotherapy drug be ready, patients will receive chemotherapy. After the chemotherapy, patients go to the cooling cap area (room) and wear the cooling cap additional 20 minute for Taxane and 90 minute for other drugs, respectively.
[Problem] To provide a method for producing extracellular particles usable for a vaccine for a swine infectious disease. [Solution] A method for producing extracellular particles that comprises: infecting swine cells, which can be infected with PRRS virus, with the virus at a moi (multiple of infection) concentration of 0.01-1.0 and, at the same time, adding interferon (INF) thereto; removing lysed cells by washing; and adding a culture solution to the unlysed cells remaining in the incubator, said unlysed cells containing a large amount of persistently virus-infected cells. After repeating the steps for washing and for adding the culture solution a preset number of times, extracellular particles are separated and purified from the remaining persistently virus-infected cells. Cells have individual differences (individuality) and, therefore, different sensitivities to interferon (IFN). Accordingly, not all cells become persistently infected even under the same experimental conditions. Experiment 2 in FIG. 2 shows an example in which the cells did not become persistently virus-infected cells even under the same experimental conditions. Therefore, it is necessary to analyze the proteins expressed by the cells after infection with the virus, and to select and clone the most promising persistently infected cells for vaccine production.
PURPOSE:To obtain an economically advantageous new peptide, having a specific amino acid sequence, capable of exhibiting inhibiting action on gastric acid secretion without any side effect, useful as an inhibitor of the gastric acid secretion, an antiulcer agent or a food and drink for preventing ulcer and derived from a mammalian milk or its processed product. CONSTITUTION:A whey concentrate is dissolved in water at 50 deg.C and regulated to pH 7.3. The regulated solution is then subjected to ultrafiltration through an ultrafiltration membrane having 20000 fractionation molecular weight. The resultant permeation liquid is then regulated to pH 7.0 and resubjected to ultrafiltration under the same conditions, desalted and concentrated. Water is subsequently added to dilute the concentrate. Thereby, diafiltration is carried out and the diluted concentrate is then concentrated and freeze-dried to provide a kappa-casein glycomacropeptide (GMP) crude fraction. The obtained fraction is subsequently passed through an anion exchange resin column and eluted with a 20mM tris-phosphoric acid buffer solution (pH 8.7) containing 0.3M common salt. The obtained eluted fraction is purified by a reversed phase high-performance liquid chromatography to afford the objective new peptide having an amino acid sequence expressed by the formula [(P) is phosphate group] and inhibiting action on gastric acid secretion.
Based on a wealth of research demonstrating the associations between physical health and psychosocial well-being, modern health care in the United States is characterized by an increasingly patient-centered model of care that places a premium on the holistic treatment of the patient as a physical, psychosocial, and spiritual whole. Hospital chaplains play a vital role in delivering emotional and spiritual care to a broad range of both religious and non-religious patients for a wide variety of stressors, and extensive research indicates that spiritual consults impact patient outcomes and satisfaction. However, there is remarkably little research on the "active ingredients" of chaplaincy spiritual care, and a subsequent lack of standardization and best-practice guidelines informing chaplain training and chaplain spiritual consulting. CBCT ® (Cognitively-Based Compassion Training) is a secularized compassion meditation program adapted from the Tibetan Buddhist mind training (lojong) tradition, and it may be an ideal addendum to both chaplain training programs and to the spiritual care consults provided by Emory University hospital chaplains to approximately 100,000 patients each year. This is a pilot study to explore the feasibility and impact of incorporating CBCT into the educational curriculum for chaplain residents. To this end, the researchers will (1) examine the impact of CBCT on burnout, compassion, and empathic accuracy among chaplains in training, (2) explore whether the impact persists through the end of the resident training, (3) evaluate the timing of the training within the existing curriculum to maximize its impact, (4) evaluate whether CBCT-informed interventions improve patient outcomes, and (5) explore chaplain and patient mediators of the impact of spiritual care consults on patient outcomes. Data acquired in this pilot study will be used to estimate efficacy and to inform a randomized controlled trial.
It has been over 80 years since Gibbs et al showed how the electroencephalogram (EEG) systematically changed in concurrence with increasing doses of hypnotic drugs such as penthobarbital and Ether. The study concluded that "Electroencephalography may therefore be of value in controlling depth of anesthesia and sedation". In spite of a solid documentation of the systematic connection between dosing of anesthetic drugs, EEG-patterns and level of sedation/anesthesia , EEG-based DoA has not become a part of standard of care in anesthetic management. There is abundant evidence of how different anesthetic drugs leads to characteristic fluctuations in human brain electrical activity, relating to depth of anesthesia, anesthetic drug of choice, and age . These anesthetic induced fluctuations are readily visible as changes in the patients EEG.

Anesthetic drugs are usually administered in pharmacological models based on a population taking into account their age, weight and height. However, there is a significant difference in how patients respond to these models. In adults there is evidence that the doses needed to achieve consciousness varies with a factor of 2 above and below suggested doses. In under-dosing of anesthetics there is a risk of peroperative awareness . On the other hand there is also evidence that overdosing of anesthetics has harmful effects; children receiving more than 4% Sevoflurane can demonstrate epileptiform activity , and adults overdosing into "burst suppression" during anesthesia has a higher risk of postoperative delirium (POD) and increased occurrence of postoperative cognitive dysfunction (POCD) .

Bispectral Index (BIS) is an algorithm developed by Aspect Medical Systems in 1994, which is based on weighted sums of EEG subparameters to present an index from 0 to 100 for depth of anesthesia, where 100 is wide awake, and 0 is an isoelectric EEG. The BIS target for a deep enough anesthesia is set to be between 40 and 60. The BIS number is often in concurrence with other clinical observations related to anesthetic depth, however there is also an experience of divergence. BIS and other EEG-based indices are programmed from adult cohorts, and cannot be directly trusted in children, or the elderly . There is also an incapability in these preprogrammed indices (BIS and other) to integrate how specific anesthetic drugs affect the EEG, and thenceforth the BIS value. An example of this is how the drug Ketamine induces a specific gamma-frequency in the EEG, which the BIS-index translate as a lighter anesthesia, even though the drug is administered "on top of" an already deep level of anesthesia.
Worldwide, gastrointestinal (GI) cancer is recognized as one of the leading malignancies diagnosed in both genders, with mortality largely attributed to metastatic dissemination. It has been identified that in GI cancer, a variety of signaling pathways and key molecules are modified, leading to the emergence of an immunotolerance phenotype. Such modifications are pivotal in the malignancy's evasion of immune detection. Thus, a thorough analysis of the pathways and molecules contributing to GI cancer's immunotolerance is vital for advancing our comprehension and propelling the creation of efficacious pharmacological treatments. In response to this necessity, our review illuminates a selection of groundbreaking cellular signaling pathways associated with immunotolerance in GI cancer, including the Phosphoinositide 3-kinases/Akt, Janus kinase/Signal Transducer and Activator of Transcription 3, Nuclear Factor kappa-light-chain-enhancer of activated B cells, Transforming Growth Factor-beta/Smad, Notch, Programmed Death-1/Programmed Death-Ligand 1, and Wingless and INT-1/beta-catenin-Interleukin 10. Additionally, we examine an array of pertinent molecules like Indoleamine-pyrrole 2,3-dioxygenase, Human Leukocyte Antigen G/E, Glycoprotein A Repetitions Predominant, Clever-1, Interferon regulatory factor 8/Osteopontin, T-cell immunoglobulin and mucin-domain containing-3, Carcinoembryonic antigen-related cell adhesion molecule 1, Cell division control protein 42 homolog, and caspases-1 and -12.
Anesthesia induction with propofol 2.5mg/kg, rocuronium bromide 0.6mg/kg, naborphine 0.2mg/kg，esketamine 0.3mg/kg, intubation was performed when BIS value reached 40-60. Intraoperative pump injection of propofol 4-12 mg/kg·h and esketamine 0.3～0.5mg/kg·h. Ultrasound-guided transversus abdominis plane block (with 0.375% ropivacaine 40ml) will be implemented preoperatively. Ondansetron 8mg and naborphine 0.2mg/kg will be given after surgery. For PCA, naborphine 2mg/kg + dexmedetomidine 2μg/kg + ondansetron 24mg.
The invention relates to an oxaceprol crystal and composition comprising the same. The characteristic peaks in an X-ray powder diffraction pattern of the oxaceprol crystal measured by Cu-K[alpha] rays are shown at 2[theta] of 4.8 degrees, 6.6 degrees, 11.2 degrees, 12.6 degrees, 14. 6 degrees, 15.5 degrees, 17.8 degrees, 19.1 degrees, 20.1 degrees, 21.5 degrees, 23.9 degrees, 27.2 degrees, 30.5 degrees and 33.2 degrees. Dissolvability tests show that the crystal reduces solubility in water at a certain degree. The crystal can be further used for preparing pharmaceutically acceptable tablets such as sustained release tablets. Since the solubility in water of the crystal is reduced, drug release behavior of the sustained release tablets prepared by the crystal is improved significantly, and stability of the sustained release tablets prepared by the crystal is more excellent.
Patients receive trastuzumab deruxtecan IV over 30-90 minutes on day 1 and olaparib PO BID on days 1-21 or days 8-14 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients taking olaparib BID on days 1-21 undergo collection of blood samples at the following times: baseline, days 1, 2, 8, and 15 of cycle 1, day 1 of cycle 2, days 1, 8, and 15 of cycle 3, day 1 of cycle 4, day 1 of every fourth cycle after cycle 4 and then at treatment end. Patients taking olaparib BID on days 8-14 undergo collection of blood samples at the following times: baseline, days 1, 2, 8, 9, and 15 of cycle 1, days 1 and 8 of cycle 2, days 1, 8, and 15 of cycle 3, day 1 of cycle 4, day 1 of every fourth cycle after that, and at treatment end. Patients undergo biopsy at baseline, and then on day 3 or day 10 of cycle 1. Patients also undergo echocardiography and CT throughout the trial.
This groups will complete a pre survey and will then watch the 10-minute educational video on cervical cancer screening and prevention prior to seeing their provider. Patients will then see the provider and will complete a post survey following appointment.
Patients receive rituximab IV on day 1 of each cycle and CC-99282 PO QD on days 1-14 of each cycle. Treatment repeats every 28 days for up to 6 cycles of rituximab and up to 24 cycles of CC-99282 in the absence of disease progression or unacceptable toxicity. Patients also undergo PET/CT and collection of blood samples throughout the trial. Patients may undergo biopsy at screening.
Delirium is a neuropsychiatric syndrome characterized by an acute alteration in attention, awareness, arousal and cognition, precipitated by an acute illness, intoxication, trauma or surgery. It is highly prevalent in older, frail and acutely hospitalized patients, and associated with poor outcomes, with few effective treatment alternatives. Non-pharmacological interventions and music show promising effects.

This study protocol aims to determine whether music interventions (MIs) delivered by a credentialed music therapist, are feasible and effective for regulating delirium symptoms in acute geriatric patients and whether the standardized delirium tools are sensitive to detect observable responses. Primary, feasibility outcomes are evaluating recruitment rate, treatment fidelity and adherence, as well as feasibility and accuracy in data collection procedures. Main effect-outcome is delirium severity, but delirium duration, cognitive status, length of hospital stay, and medication use will also be recorded. The randomised repeated measures controlled trial design will record the participant responses before and after exposure to MIs (+/- 2 hours). Participants with delirium from an acute geriatric ward will be randomized to either live or recorded MI. Each intervention will be delivered to n=30 participants (n=60 in total), for 30 minutes, over three consecutive days. Ethical approval has been obtained from Regional Ethics Committee South East Norway.
The present invention relates to lipid based nanoparticles or liposomes that are sensitive to ultrasonic energy, compositions containing these particles, methods for delivering one or more active agents using the particles, and methods for preparing the particles. The nanoparticles and liposomes encapsulate active agents such as chemotoxins, genes, virus vectors, proteins, peptides, antisense oligonucleotides, carbohydrates, and stem cells. The particles contain an aqueous core, at least one active agent located within the aqueous core, and a lipid bilayer or membrane that encapsulates the active agent within the aqueous core. The lipid bilayer may comprise a primary phospholipid and a lysolipid that preferably have different acyl chain lengths, making the lipid bilayer sensitive to ultrasound. Ultrasound may be used to track the particles as they move throughout the body. When the ultrasonic energy reaches a certain pressure, the lipid bilayer will break apart, releasing the active agent.
OBJECTIVES: I. Determine the objective response rate in patients with advanced, recurrent, or inoperable ovarian epithelial cancer treated with aminocamptothecin as second-line therapy. II. Determine the toxic effects of this regimen in these patients. III. Correlate the topoisomerase-I levels with response in patients with accessible tumors treated with this regimen.

OUTLINE: Patients are stratified according to disease (measurable vs nonmeasurable). (The measurable disease stratum closed to accrual effective 08/1998.) Patients receive aminocamptothecin IV continuously on days 1-3. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (CR) receive 4 additional courses past CR. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 60 patients (30 per stratum) will be accrued for this study within approximately 15 months. (The measurable disease stratum closed to accrual effective 08/1998.)
FIELD: cosmetic industry; production of creams for skin care in the form of day and night creams. SUBSTANCE: method involves preparation of growth factors which stimulate proliferation of epithelium cells and fibroblasts of man's skin, introduction in their base (in the form of gel) components and their mixing. Additionally introduced in cream is nutrient medium of culture of man and/or animal cells and biologically active substances of natural or chemical origin. Growth factors are prepared and used in cream in composition of nutrient medium containing growth factors including interleikin-2, erytropoetin, epidermal growth factor and leukocytic growth hormone, products of metabolism of leukocytes cells of men and/or animals at the following quantitative ratio of cream components, mas.%: nutrient medium with growth factors and metabolism products of leukocytes cells , 0.7-8.5; biologically active substances of natural and chemical origin, 7.0-27.0; base in the form of gel, the balance. EFFECT: improved preparation technology; increased regenerating action. 2 cl, 4 ex
Diabetic cardiomyopathy (DCM) is a complication of diabetes mellitus characterized by heart failure and cardiac remodeling. Previous studies show that tetrahydroberberrubine (THBru) retrogrades cardiac aging by promoting PHB2-mediated mitochondrial autophagy and prevents peritoneal adhesion by suppressing inflammation. In this study we investigated whether THBru exerted protective effect against DCM in db/db mice and potential mechanisms. Eight-week-old male db/db mice were administered THBru (25, 50 mg·kg-1·d-1, i.g.) for 12 weeks. Cardiac function was assessed using echocardiography. We showed that THBru administration significantly improved both cardiac systolic and diastolic function, as well as attenuated cardiac remodeling in db/db mice. In primary neonatal mouse cardiomyocytes (NMCMs), THBru (20, 40 μM) dose-dependently ameliorated high glucose (HG)-induced cell damage, hypertrophy, inflammatory cytokines release, and reactive oxygen species (ROS) production. Using Autodock, surface plasmon resonance (SPR) and DARTS analyses, we revealed that THBru bound to the domain of the receptor for advanced glycosylation end products (RAGE), subsequently leading to inactivation of the PI3K/AKT/NF-κB pathway. Importantly, overexpression of RAGE in NMCMs reversed HG-induced inactivation of the PI3K/AKT/NF-κB pathway and subsequently counteracted the beneficial effects mediated by THBru. We conclude that THBru acts as an inhibitor of RAGE, leading to inactivation of the PI3K/AKT/NF-κB pathway. This action effectively alleviates the inflammatory responses and oxidative stress in cardiomyocytes, ultimately leading to ameliorated DCM.
Substituted indoloquinoxalines of general formula (I), wherein R1? represents one or several substituents selected from halogen, lower alkyl/alkoxy group, trifluoromethyl group, trichloromethyl group; X is a group -(CH2?)n?-R2? wherein R2? represents a nitrogen containing basic residue and n is an integer of from 1 to 4 and R3? represents hydrogen, lower alkyl/cycloalkyl group having not more than 4 carbon atoms, and the physiologically acceptable addition products of the compounds with acids and halogen adducts. Also methods for preparing said compounds are described. The novel indoloquinoxalines have antiviral effect and have effect against cancer.
The method for treating the arterial hypertension comprises the physiotherapeutic procedures affecting the backbone divisions. The drug therapy comprises beta-blocker and calcium antagonist. In the morning, the single dose of beta-blocker is taken. In 1.5 h, the cervical and thoracic divisions of the backbone are exposed to the ultrasound paravertebrally. Then the single dose of calcium antagonist is given. Three hours later, the sacral and lumbar divisions of the backbone are exposed to the ultrasound.
Long-COVID (having symptoms lasting 3 months or longer post-infection) is an emerging public health concern, yet research on whether COVID-19 booster vaccines can mitigate this condition is limited. This study examined associations between booster uptake and long-COVID prevalence among U.S. adults. Data were analyzed from 8757 adults aged 18 years or older with a history of COVID-19 infection from the 2022 National Health Interview Survey. Weighted prevalence and logistic regression models examined relationships between self-reported COVID-19 booster vaccination status and long-COVID, adjusting for sociodemographics and health factors. 19.5 % reported experiencing long-COVID. Individuals receiving the COVID-19 booster vaccine had significantly lower adjusted odds of long-COVID (OR 0.75, 95 % CI 0.61-0.93) compared to unvaccinated individuals. Overall, these findings suggest that COVID-19 booster vaccination is associated with a reduced prevalence of long-COVID among the U.S. adult population, underscoring the importance of optimizing booster uptake to mitigate the long-term impacts of COVID-19.
Epileptic seizure prediction plays a crucial role in enhancing the quality of life for individuals with epilepsy. Over recent years, a multitude of deep learning-based approaches have emerged to tackle this challenging task, leading to significant advancements. However, the 'black-box' nature of deep learning models and the considerable interpatient variability significantly impede their interpretability and generalization, thereby severely hampering their efficacy in real-world clinical applications. To address these issues, our study aims to establish an interpretable and generalizable seizure prediction model that meets the demands of clinical diagnosis. Our method extends self-interpretable prototype learning networks into a novel domain adaptation framework designed specifically for cross-patient seizure prediction. The proposed framework enables patient-level interpretability by tracing the origins of significant prototypes. For instance, it could provide information about the seizure type of the patient to which the prototype belongs. This surpasses the existing sample-level interpretability, which is limited to individual patient samples. To further improve the model's generalization capability, we introduce a contrastive semantic alignment loss constraint to the embedding space, enhancing the robustness of the learned prototypes. We evaluate our proposed model using the Freiburg intracranial electroencephalography (iEEG) dataset, which consists of 20 patients and a total of 82 seizures. The experimental results demonstrated a high sensitivity of 79.0%, a low false prediction rate of 0.183, and a high area under the receiver operating characteristic curve (AUC) value of 0.804, achieving state-of-the-art performance with self-interpretable evidence in contrast to the current cross-patient seizure prediction methods. Our study represents a significant step forward in developing an interpretable and generalizable model for seizure prediction, thereby facilitating the application of deep learning models in clinical diagnosis.